SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Galapagos Islands -- Ignore unavailable to you. Want to Upgrade?

To: Jorj X Mckie who wrote (13975)11/21/2002 2:06:15 PM
From: tuck  Respond to of 57110
 
Yeah, definitely forget I mentioned CEPH as a short candidate on any fundamental basis. Further research with a little help from my friends shows Provigil is safe from generics. Not they won't go through the motions. A case for shorting CEPH for technical reasons could be made, but probably best made by someone more competent than I at that stuff.

CHIR, otoh, is a possibility (starting to check it out), in addition to the others I mentioned. And AFFX. I like them, but they are getting pricey again.

Cheers, Tuck



To: Jorj X Mckie who wrote (13975)11/21/2002 2:32:29 PM
From: TimeToMakeTheInvs  Read Replies (2) | Respond to of 57110
 
I remember the days when shorting BRCM at 20 or 21 was a slam dunk money maker, LOL. tim


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News